Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3338011> ?p ?o }
Showing triples 1 to 49 of
49
with 100 triples per page.
- Q3338011 subject Q22570441.
- Q3338011 subject Q7336348.
- Q3338011 subject Q8790228.
- Q3338011 abstract "Nemifitide (INN-00835) is a novel antidepressant drug with a pentapeptide structure similar to that of melanocyte-inhibiting factor (MIF-1) and the amino acid sequence 4-F-Phe-4-OH-Pro-Arg-Gly-Trp-NH2. It is under development by Tetragenex (previously Innapharma, Inc.) for the treatment of major depressive disorder. It has been given to over 430 people over the course of 12 clinical trials throughout a little over the past decade and has reached Phase III studies, but has not yet been approved for marketing in any country.Nemifitide has shown mixed efficacy in alleviating depressive symptoms, but in the cases in which it has worked it has proven to have a rapid onset of action (~5–7 days), few to no side effects, and an excellent safety profile. However, it is inactive orally and must be administered via subcutaneous injection. Remarkably, despite having a very short half-life of only 15–30 minutes, in most or all studies assessing its efficacy nemifitide has been administered merely once daily via the subcutaneous route and yet is effective for depression.The mechanism of action of nemifitide is unclear, but since MIF-1 has been demonstrated to have similar antidepressant effects it may act in an analogous manner. Possibly of interest however is that nemifitide binds to several receptors including 5-HT2A (where it has been shown to act as an antagonist), NPY1, bombesin, and MC4 and MC5, though at only micromolar concentrations. Whether any of these relatively weak actions are of any clinical significance is unclear.".
- Q3338011 atcPrefix "none".
- Q3338011 casNumber "173240-15-8".
- Q3338011 fdaUniiCode "RO19OXA9NG".
- Q3338011 iupacName "(4R)-4-hydroxy-L-prolyl-N5-(diaminomethylidene)-L-ornithylglycyl-N-[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]-L-tryptophanamide".
- Q3338011 pubchem "177265".
- Q3338011 thumbnail Nemifitide.svg?width=300.
- Q3338011 wikiPageWikiLink Q13566124.
- Q3338011 wikiPageWikiLink Q14891424.
- Q3338011 wikiPageWikiLink Q1550789.
- Q3338011 wikiPageWikiLink Q18028921.
- Q3338011 wikiPageWikiLink Q18028923.
- Q3338011 wikiPageWikiLink Q2035485.
- Q3338011 wikiPageWikiLink Q208467.
- Q3338011 wikiPageWikiLink Q22570441.
- Q3338011 wikiPageWikiLink Q285166.
- Q3338011 wikiPageWikiLink Q30612.
- Q3338011 wikiPageWikiLink Q3269441.
- Q3338011 wikiPageWikiLink Q3271540.
- Q3338011 wikiPageWikiLink Q410943.
- Q3338011 wikiPageWikiLink Q425105.
- Q3338011 wikiPageWikiLink Q42844.
- Q3338011 wikiPageWikiLink Q47270.
- Q3338011 wikiPageWikiLink Q4940670.
- Q3338011 wikiPageWikiLink Q500256.
- Q3338011 wikiPageWikiLink Q672821.
- Q3338011 wikiPageWikiLink Q6811443.
- Q3338011 wikiPageWikiLink Q7094540.
- Q3338011 wikiPageWikiLink Q7165041.
- Q3338011 wikiPageWikiLink Q7336348.
- Q3338011 wikiPageWikiLink Q76560.
- Q3338011 wikiPageWikiLink Q8386.
- Q3338011 wikiPageWikiLink Q8790228.
- Q3338011 atcPrefix "none".
- Q3338011 casNumber "173240".
- Q3338011 iupacName "-4".
- Q3338011 pubchem "177265".
- Q3338011 unii "RO19OXA9NG".
- Q3338011 type ChemicalSubstance.
- Q3338011 type Drug.
- Q3338011 type ChemicalObject.
- Q3338011 type Thing.
- Q3338011 type Q8386.
- Q3338011 comment "Nemifitide (INN-00835) is a novel antidepressant drug with a pentapeptide structure similar to that of melanocyte-inhibiting factor (MIF-1) and the amino acid sequence 4-F-Phe-4-OH-Pro-Arg-Gly-Trp-NH2. It is under development by Tetragenex (previously Innapharma, Inc.) for the treatment of major depressive disorder.".
- Q3338011 label "Nemifitide".
- Q3338011 depiction Nemifitide.svg.